What Is the Digital Care Act Germany? the 2026 Diga Reforms: Reimbursement, Pricing and Market Access

What is the Digital Care Act Germany, and why does it matter more in 2026 than at any point since the law was enacted? Germany’s Digitale-Versorgung-Gesetz (DVG), commonly known as the Digital Healthcare Act, created the world’s first statutory pathway for doctors to prescribe reimbursable software-based medical applications, digital health applications, or Digitale Gesundheitsanwendungen (DiGA). The 2026 DiGA reforms tighten that framework substantially, introducing mandatory outcomes monitoring, performance-based pricing mechanics, and stricter evidence thresholds for permanent listing on the BfArM DiGA directory. For manufacturers, in-house market-access teams, payers and their legal advisors, the changes demand immediate action across contracting, evidence generation and price negotiation strategy.

TL;DR, Key Takeaways for Market-Access Teams

The Digital Care Act Germany established the DiGA fast-track pathway in 2019. The 2026 DiGA reforms add significant compliance and commercial complexity. Every manufacturer with a listed or pipeline DiGA should act on these six priorities now:

• Design an outcomes-monitoring plan. Mandatory real-world outcomes data collection is now a condition of continued listing, define endpoints, data flows and reporting cadence before your next BfArM submission window.
• Audit pricing contracts for performance-linked clauses. Industry reporting indicates that a share of the negotiated price, reported at a minimum of 20 %, must be tied to demonstrated patient outcomes.
• Prepare your evidence dossier early. Tightened thresholds mean relying on retrospective registry data alone will no longer suffice for permanent listing; plan prospective studies now.
• Review AMNOG interaction points. If your DiGA is used alongside a reimbursed pharmaceutical, G-BA benefit-assessment processes may apply in parallel.
• Update GDPR and patient-consent frameworks. Outcomes monitoring generates personal health data subject to strict EU and German data-protection rules, consent mechanisms, data-processing agreements and retention policies must be audit-ready.
• Engage payer and GKV negotiation counsel. New pricing mechanics shift bargaining power; early legal and health-economic input into contract negotiations is critical for market access in digital health in Germany.

What is the Digital Care Act (DVG)? Legislative Background and Definitions

DVG: Purpose and Scope

The Digitale-Versorgung-Gesetz (DVG) was adopted by the German Bundestag in November 2019 and entered into force on 19 December 2019. Its central objective was to accelerate digitalisation across Germany’s statutory health-insurance system (Gesetzliche Krankenversicherung, GKV) by creating a legal entitlement for insured persons to receive prescribed digital health applications (DiGA) at the expense of their statutory health insurer. The DVG also expanded the use of telemedicine, electronic health records and secure digital infrastructure within the healthcare system.

What Qualifies as a DiGA

A DiGA is a software-based medical device, typically a mobile application or web-based programme, that supports patients in detecting, monitoring, treating or alleviating diseases, injuries or disabilities. To qualify for listing on the BfArM DiGA directory, a product must meet several cumulative requirements:

• CE marking. The application must be classified and CE-marked as a medical device of risk class I or IIa under the EU Medical Device Regulation (MDR).
• Positive healthcare effects. The manufacturer must demonstrate either a medical benefit (medizinischer Nutzen) or a patient-relevant structural or procedural improvement (patientenrelevante Struktur- und Verfahrensverbesserung).
• Data protection and information security. The DiGA must comply with German and EU data-protection requirements, including the GDPR, and meet BfArM’s published data-security baseline.
• Interoperability and quality standards. The device must be capable of operating within the digital health infrastructure established under the DVG framework.

Only products that satisfy these criteria can be listed, either permanently or on a temporary basis, in the official DiGA directory maintained by BfArM, Germany’s federal medicines and medical-devices regulator.

How Germans Pay for Healthcare, and Why GKV Matters for DiGA

Germany operates a dual health-insurance system. Approximately 90 % of the population is covered by the statutory health-insurance scheme (GKV), which is mandatory for employees below a defined income threshold. The remaining population, including higher-income earners and self-employed individuals, may opt for private health insurance (PKV). The DVG’s reimbursement provisions apply primarily to the GKV-insured population, making GKV the critical payer pathway for DiGA manufacturers seeking broad market access in digital health in Germany.

What Changed in 2026: The Core DiGA Reforms

The 2026 DiGA reforms represent the most significant amendments to the Digital Healthcare Act since its inception. They respond to longstanding policy concerns about the sustainability of free pricing during temporary listing and the absence of robust post-market evidence requirements. The practical effect of the reforms is threefold: manufacturers face new monitoring mandates, pricing is increasingly tied to demonstrated value, and the evidentiary bar for permanent listing has been raised.

New Obligations: Monitoring, Reporting and Performance-Linked Pricing

The 2026 amendments introduce several concrete obligations for DiGA manufacturers:

• Mandatory outcomes monitoring. Every listed DiGA, whether temporarily or permanently, must collect and report structured outcomes data on defined clinical or patient-relevant endpoints. Monitoring plans must be submitted to BfArM alongside or shortly after the listing application.
• Periodic reporting cadence. Manufacturers are required to submit outcomes reports at defined intervals. Industry observers expect reporting cycles of between six and twelve months, aligned with the temporary listing evaluation window.
• Performance-linked pricing share. A defined share of the DiGA’s reimbursement price must be contractually linked to outcomes performance. Industry sources report that this share is set at a minimum of 20 % of the negotiated price, though the precise threshold should be confirmed against the final regulatory text. If outcomes targets are not met, this portion is subject to repayment or price reduction.
• Tightened temporary listing. The temporary listing window, originally up to twelve months, with the possibility of a single twelve-month extension, is now accompanied by stricter interim evidence milestones. Early indications suggest that manufacturers failing to meet interim evidence requirements may face early delisting rather than an automatic extension.

Timeline of Implementation

DiGA Reimbursement Germany: BfArM Listing, Temporary Coverage and Payer Interaction

DiGA reimbursement in Germany follows a structured pathway that begins with a manufacturer application to BfArM and culminates in negotiated pricing with the GKV-Spitzenverband (GKV-SV), the central association of statutory health insurers. Understanding each step is essential for any manufacturer pursuing market access in digital health in Germany.

How to Use the DiGA Directory for Market Access

The BfArM DiGA directory, commonly referred to as the DiGA apps list, is the official register of all approved digital health applications eligible for GKV reimbursement. Once a DiGA is listed, physicians and psychotherapists can prescribe it, and statutory health insurers must reimburse the cost. Manufacturers should treat the DiGA directory listing as the central market-access gateway: without it, no statutory reimbursement is possible. The full directory is publicly accessible on the BfArM website.

Where GKV Fits In: Statutory Scope and Payer Roles

GKV membership is mandatory for the vast majority of the German workforce. This means that DiGA reimbursement reaches approximately 73 million insured persons. The GKV-Spitzenverband negotiates framework pricing with manufacturers for permanently listed DiGAs, while temporarily listed DiGAs benefit from manufacturer-set prices for a limited period. Under the 2026 reforms, even temporarily listed DiGAs must now satisfy interim evidence and outcomes-reporting requirements.

Reimbursement Pathway Steps

DiGA Performance-Based Pricing Reforms and AMNOG Interactions

The 2026 DiGA reforms fundamentally alter how prices are determined and sustained. The previous system allowed manufacturers to set prices freely during the temporary listing period, with negotiated pricing only following permanent listing. Under the revised framework, DiGA performance-based pricing introduces a value-linked component from the earliest stages of reimbursement.

The mechanism works as follows: a defined share of the reimbursement price, industry reporting places this at a minimum of 20 % of the total negotiated amount, is contractually contingent on the DiGA meeting pre-agreed outcomes targets. If monitoring data shows that the application fails to achieve these benchmarks, the performance-linked share is subject to repayment to the GKV insurer or an equivalent price reduction in subsequent periods. The likely practical effect will be that manufacturers must invest significantly more in post-market evidence generation and outcomes analytics than was previously necessary.

When AMNOG Applies to Digital Health

AMNOG, Germany’s Arzneimittelmarktneuordnungsgesetz, governs the benefit assessment and pricing of pharmaceuticals. While DiGA are not pharmaceuticals, AMNOG principles increasingly intersect with DiGA pricing in specific scenarios:

• Combination products. Where a DiGA is marketed alongside or as a companion to a reimbursed pharmaceutical (e.g., a digital therapeutic used in conjunction with a prescription medication), the G-BA may conduct a parallel benefit assessment under AMNOG procedures.
• Hybrid device-drug products. Products that straddle the boundary between software medical device and medicinal product may trigger dual assessment pathways.
• Reference pricing. The G-BA and GKV-SV may use AMNOG-established reference pricing and health-technology assessment (HTA) methodologies as benchmarks when negotiating DiGA prices, particularly for performance-linked share calculations.

Pricing Negotiation Tactics and Contractual Protections

Manufacturers should approach GKV-SV price negotiations with a comprehensive strategy:

• Cap downside exposure. Negotiate a floor on the performance-linked repayment so that a single poor reporting cycle does not trigger disproportionate financial consequences.
• Phase price adjustments. Tie price increases to pre-agreed outcome milestones rather than accepting binary pass/fail triggers.
• Secure audit and data-access rights. Ensure contractual entitlement to access GKV claims data relevant to outcomes verification.
• Define dispute-resolution clauses. Include arbitration or expert-determination mechanisms for disagreements over whether outcomes targets have been met.

How DiGA Price Reforms Intersect with AMNOG

Mandatory Outcomes Monitoring: What to Measure, Legal and Data-Protection Considerations

The 2026 DiGA reforms make outcomes monitoring a regulatory requirement rather than a voluntary quality measure. Manufacturers must design and implement monitoring frameworks that satisfy both BfArM’s evidentiary expectations and German and EU data-protection law. A credible monitoring plan is now a precondition for initial listing and a determinant of ongoing reimbursement.

The monitoring plan should address the following components:

• Endpoint selection. Define primary and secondary outcomes, these may be clinical endpoints (e.g., symptom reduction scores, hospitalisation rates) or patient-relevant structural improvements (e.g., adherence rates, time-to-treatment access).
• Data-collection frequency. Align reporting cycles with BfArM’s expected cadence, early indications suggest six- to twelve-month intervals.
• Analytics and reporting infrastructure. Establish data pipelines, statistical methodologies and quality-assurance protocols before the listing date.
• Third-party vendor engagement. If monitoring is outsourced, data-processing agreements compliant with Article 28 GDPR must be in place.

Data Protection and Patient Consent Checklist

• Obtain explicit informed consent for outcomes-data collection under Article 9(2)(a) GDPR where health data is processed.
• Implement data minimisation, collect only the data points required for the defined endpoints.
• Establish retention schedules aligned with the monitoring and reporting period, plus any statutory archiving requirements.
• Appoint a Data Protection Officer (DPO) if not already in place, and conduct a Data Protection Impact Assessment (DPIA) for the monitoring programme.

Contracts: Commissioning Monitoring Vendors and Payer Data-Use Clauses

Where manufacturers commission third-party providers for analytics or data management, contracts should include clear data-controller/processor delineation, sub-processing restrictions, audit rights and incident-notification obligations. Payer-side data-use clauses should be negotiated alongside the pricing agreement to ensure that GKV claims data, when shared, is used exclusively for outcomes verification and is subject to purpose limitation.

Reporting Obligations by Entity Type

Evidence and Dossier: Building the Case for Permanent Listing and Price

The evidence required for permanent DiGA listing has always been higher than for temporary listing, but the 2026 reforms raise the bar further. Manufacturers must now present a comprehensive evidence dossier that not only demonstrates positive healthcare effects but also supports the credibility of the performance-linked pricing share.

Best-Practice Evidence Plan

The evidence hierarchy for DiGA broadly follows the principles applied in health-technology assessment:

• Randomised controlled trials (RCTs) remain the gold standard and are strongly preferred by BfArM for permanent listing applications.
• Prospective observational studies may supplement RCTs, particularly for patient-relevant structural and procedural improvements.
• Real-world evidence (RWE) and registry data can support but rarely replace trial-level evidence under the tightened 2026 requirements.
• Health-economic modelling is increasingly relevant for pricing negotiations with GKV-SV, especially where the manufacturer seeks to justify a higher performance-linked price share.

Reimbursement payment amounts are ultimately set through negotiation between the manufacturer and the GKV-Spitzenverband following permanent listing. Where negotiations fail, an arbitration body (Schiedsstelle) determines the price. The performance-linked share is embedded within the final negotiated or arbitrated price, meaning that the quality of the evidence dossier directly influences the commercial return on the product.

Practical Checklist and Timeline for Manufacturers

Use the following action plan to structure your compliance and market-access preparations around the 2026 DiGA reforms:

Negotiation Templates and Contract Clauses to Protect Manufacturers

The shift to DiGA performance-based pricing demands that manufacturers build legal protections into every payer contract. The following negotiation levers should be standard in any GKV-SV pricing agreement under the 2026 framework:

• Capped downside. Limit the maximum repayable performance-linked share per reporting cycle (e.g., cap at the reported 20 % minimum, with no compounding across periods).
• Phased price escalation. Link price increases to the achievement of pre-defined outcome milestones at each reporting interval, rather than a single pass/fail gate.
• Audit rights. Secure the manufacturer’s right to independently verify GKV claims data used to assess outcomes performance.
• Data-access clauses. Contractually guarantee timely access to anonymised patient-level data required for outcomes analytics.
• Termination triggers. Define the circumstances under which either party may terminate the pricing agreement, for example, if regulatory changes materially alter the performance-linked framework.
• Expert determination. Include a mechanism for independent expert resolution of disputes over whether outcomes targets have been achieved, avoiding protracted arbitration.

Conclusion: Immediate Legal Actions for Market Access in Digital Health in Germany

Understanding what is the Digital Care Act Germany now requires far more than a summary of the original 2019 legislation. The 2026 DiGA reforms introduce binding obligations that reshape reimbursement, pricing and evidence generation for every digital health application on the German market. Three immediate legal actions will determine whether manufacturers maintain, or lose, their competitive position:

1. Implement an outcomes-monitoring plan that satisfies BfArM requirements and is GDPR-compliant from day one.
2. Restructure pricing contracts to accommodate performance-linked repayment obligations, with adequate downside protections.
3. Engage specialist legal counsel in Germany experienced in DiGA reimbursement, AMNOG interactions and GKV-SV negotiations to audit your current market-access strategy against the 2026 requirements.

Sources

1. Bundesministerium für Gesundheit (BMG), Digital Healthcare Act
2. BfArM, Digital Health Applications (DiGA)
3. PMC / National Institutes of Health, Digital health applications from a government-regulated perspective
4. Nature, Germany’s digital health reforms
5. ICLG, Digital Health Laws and Regulations Report 2026 (Germany)
6. Germany Trade & Invest (GTAI), Digital Health Market in Germany